Chiesi Ventures
Corporate VCBoston · Seed–Series A · 2 people tracked
Find your way into Chiesi Ventures
228 people in our graph share verified history with the Chiesi Ventures team — schools, employers, funds. One of them is your warm intro.
Investment thesis
Chiesi Ventures is a corporate venture capital firm dedicated to rare and orphan diseases. It seeks to complement the strategic interests of its parent, the Chiesi Group, by backing early-stage development opportunities and treatments for rare diseases. The firm also works to broaden the Chiesi network across Europe and the United States, building relationships with universities, other venture capital investors, rare disease patient organizations, and entrepreneurial companies developing therapies in this space.
Source: firm website, verified Aug 3, 2026.
Team · 2 people
from the firm's website & public directories
What they invest in
from 9 of 9 portfolio companiesBiotech ×9Healthtech ×5Medical Devices ×2Deep Tech ×1
HQs:United States×7Spain×1
Who they back
founder profiles across 8 portfolio companiesFounding team size:solo founder×52 founders×3
Investments · 9 tracked
founders shown can be your intro pathBy year:2016 · 12015 · 12 dated
4DMT is a late-stage biotechnology company that develops gene delivery systems and genetic therapeutics targeting specific tissue types for various diseases.
BiotechHealthtechEmeryville, US
David Kirn(Executive Officer, Director)inDavid Schaffer(Director)inTheresa Janke(Executive Officer)in
BoardSharon Tetlow(Director)Margi McLoughlin(Director)
Co-investorsAmzak HealthBerkeley CatalystBOLD LongevityPappas CapitalPfizer Venture InvestmentsCasdin Capital+1 more
Aura Biosciences develops Virus-Like Drug Conjugates (VDCs), a platform using Virus-Like Particles conjugated with drugs or loaded with nucleic acids to target solid tumors.
BiotechHealthtechMedical DevicesCambridge, US
Elisabet de los Pinos, Ph.D.(Executive Officer, Director)Elisabet de los Pinos(Founder)inMichael Wyzga(Executive Officer)Dale Pfost, Ph.D.(Director)Alan E. Walts, Ph.D.(Director)Lewis Geffen(Executive Officer)
Co-investorsAdvent Life SciencesDroia VenturesForesite CapitalJazzya InvestmentsMedicxiMyelin VC+4 more
Mirum Pharmaceuticals is a biopharmaceutical company that develops and delivers therapies for people living with rare diseases.
BiotechHealthtechSan Diego, US
Chris Peetz(Co-founder & Chief Executive Officer)inEric Bjerkholt(Executive Officer)inPeter Radovich(Executive Officer)in
BoardPatrick Heron(Director)Michael Grey(Director)Timothy Walbert(Director)
Co-investorsFrazier Life SciencesNew Enterprise Associates (NEA)RiverVest Venture PartnersNorwest Venture Partners
Developing therapies for congenital disorders of glycosylation combining replacement therapies with intracellular delivery vehicles.
BiotechSan Francisco, US
Agnes Rafalko(Executive Officer, Director)
BoardPeter C.M. McWilliams(Director)Christopher Starr(Director)
Board seatGiacomo Chiesi· per SEC Form D
Co-investorsAdvent Life SciencesCTI Life Sciences Fund L.P.Remiges Ventures, Inc.RiverVest Venture PartnersSanderling VenturesSanofi Ventures+4 more
CuraSen Therapeutics is a privately funded biopharmaceutical company developing treatments that selectively activate adrenergic receptors in the brain to restore noradrenergic signaling.
BiotechHealthtech
Anthony Fordin
Co-investorsAlta PartnersLongitude Capitalabrdn plcIntermediate Capital GroupJohnson & Johnson Innovation – JJDCNew Leaf Venture Partners+2 more
BiotechSouth San Francisco, US
John F. Fowler(Executive Officer, Director)inChristopher J. Kirk(Executive Officer, Director)
BoardDr. Gerald Chan(Director)Dr. Jean-Pierre Sommadossi(Director)
Co-investorsBay City CapitalPappas CapitalSolasta VenturesEcoR1 CapitalQiming Venture Partners
Minoryx is a registration-stage biotech company developing novel therapies for severe, orphan genetic diseases of the central nervous system, with a lead compound (leriglitazone) in clinical trials for conditions including cerebral adrenoleukodystrophy, Friedreich's Ataxia, and Rett syndrome.
BiotechDeep TechHealthtechMedical DevicesMataró, ES
Marc Martinell(Co-Founder & Chief Executive Officer)in
Co-investorsCriteria Bio VenturesFund+Invivo Capital PartnersKurma PartnersRoche Venture FundYsios Capital+1 more
BiotechMedford, US
Biju Parekkadan(Director)Brian Miller(Executive Officer, Director)
BoardMartin Heidecker(Director)Greg Bailey(Director)Rich Ganz(Director)
Co-investorsBioInnovation Capital
A biopharmaceutical company developing medicines and vaccines with a focus on clinical research and development for human health.
BiotechSan Diego, US
David Johnson(Executive Officer, Director)Cam Gallagher(Director)Scott L. Glenn(Director)
Co-investorsPappas CapitalSofinnova VenturesVedanta CapitalOrbiMed
Exits · 3
IPOs and acquisitions across the tracked portfolio4D Molecular TherapeuticsNASDAQ: FDMTAura BiosciencesNASDAQ: AURAMirum PharmaceuticalsNASDAQ: MIRM
Portfolio news
latest coverage across their companiesAura Biosciences · tickerreport.com · Aug 18, 2026
Mirum Pharmaceuticals · finance.yahoo.com · Aug 13, 2026
Kezar Life Sciences · partnology.com · Oct 21, 2025
Glycomine · finsmes.com · Apr 16, 2025
Frequently asked questions
- How many investments has Chiesi Ventures made?
- Chiesi Ventures has 9 tracked investments.
- What stage does Chiesi Ventures invest at?
- Chiesi Ventures invests at the Seed, Series A stages.
- What is Chiesi Ventures's typical check size?
- Chiesi Ventures typically writes checks of $5M.
- What sectors does Chiesi Ventures focus on?
- Chiesi Ventures focuses on Biotech, Digital Health, Healthtech, Medical Devices.
- Where is Chiesi Ventures located?
- Chiesi Ventures is headquartered in Boston, US.
- Does Chiesi Ventures lead rounds?
- Yes, Chiesi Ventures leads investment rounds.
- Who does Chiesi Ventures co-invest with?
- Chiesi Ventures most often shares deals with Pappas Capital, Advent Life Sciences, RiverVest Venture Partners, among 32 tracked co-investors.
Similar investors
Amadeus Capital Partners is a technology investment firm that backs founders building complex, science-led and deep tech businesses, supporting them over the long term as they scale internationally.
Capricorn Partners is a Belgium-based, partner-owned independent management company for alternative investment funds, investing in innovative companies across digital, health and clean technologies with an ESG focus.
Eight Roads Ventures is a venture capital firm that backs and partners with technology and healthcare companies.
Kleiner Perkins is a venture capital firm that backs founders across technology and life sciences, from early stage through growth.
Third Rock Ventures is a venture capital firm that discovers, launches, and builds life sciences and biotechnology companies developing novel medicines and therapies.